The BCL2L11 Knockout 143B Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human 143B osteosarcoma cell line. This product provides a heterogeneous pool of cells harboring targeted disruptions in the BCL2L11 gene, which encodes the pro-apoptotic BH3-only protein BIM. The polyclonal nature ensures a diverse range of loss-of-function alleles, minimizing clonal selection bias and enabling robust functional studies in bone cancer research and apoptosis signaling.
143B cells are a well-established osteosarcoma model characterized by their tumorigenic properties and rapid growth as adherent cultures. Derived from a human osteosarcoma, this cell line is widely employed to study malignant bone tumor biology, metastasis, and response to therapeutic agents. The 143B background provides a clinically relevant context for investigating apoptotic pathways in osteosarcoma, a cancer type often associated with dysregulated cell death mechanisms.
BCL2L11 (BIM) functions as a critical initiator of intrinsic apoptosis by binding and neutralizing anti-apoptotic BCL-2 family members such as BCL-2, BCL-XL, and MCL-1, thereby freeing BAX and BAK to oligomerize and permeabilize the mitochondrial outer membrane. This process triggers release of cytochrome c, leading to APAF-1-dependent activation of caspase-9 and subsequent executioner caspases including caspase-3. BIM activity is regulated by multiple upstream signals, with FOXO3, CHOP, and ERK1/2 controlling its transcription or post-translational stability, while interactions with DYNLL1 modulate its sequestration. In apoptosis pathways, BIM acts upstream of mitochondrial pro-apoptotic effectors and cytochrome c release, positioning it as a pivotal sensor of cellular stress and therapeutic insults.
Knockout of BCL2L11 in 143B cells eliminates the primary pro-apoptotic BH3-only activity, rendering the mitochondrial pathway unresponsive to stimuli that normally induce BIM-dependent cell death. This loss-of-function model enables researchers to dissect BIM-specific contributions to osteosarcoma cell survival, evaluate resistance to chemotherapeutics, and assess the efficacy of BH3 mimetics. By comparing parental and knockout populations, investigators can delineate BIM-dependent from BIM-independent apoptotic mechanisms, providing insights into how osteosarcoma cells may evade apoptosis in a tumor microenvironment. The polyclonal knockout format further supports population-level analyses that better reflect tumor heterogeneity.
These polyclonal knockout cells are suited for a range of apoptosis-focused assays. Western blotting can confirm loss of BIM and assess caspase cleavage events, while flow cytometry with Annexin V/PI enables quantification of apoptotic cell death. Downstream caspase-3/7 activity assays and cytochrome c release experiments provide functional readouts of mitochondrial permeability. MTT and colony formation assays measure cell viability and clonogenic potential in the context of chemotherapy or targeted therapy. Additionally, genotyping PCR can validate gene disruption. This model supports diverse investigations in cancer biology, including functional genomics and BH3 mimetic drug testing. For further information, please contact Ascent Research.
